Adicet Bio Inc ACET
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-01-26 |
| Shares Out. | 9,350,000 |
| Website | adicetbio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 102 |
| Net Income | -$20.2M |
| Free Cash Flow | -$91.6M |
| Total Assets | $169.4M |
| Total Liabilities | $29.3M |
| Equity | $140.1M |
About Adicet Bio Inc
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Adicet Bio Inc is a publicly traded company under the ticker symbol ACET on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)